Amicus Therapeutics, Inc. (FOLD) Posts Earnings Results, Misses Expectations By $0.10 EPS

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10), Bloomberg Earnings reports. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. During the same period in the prior year, the company earned ($0.33) EPS. Amicus Therapeutics’s quarterly revenue was up 419.0% on a year-over-year basis.

Amicus Therapeutics (NASDAQ:FOLD) traded up $0.17 during mid-day trading on Friday, reaching $13.22. 888,600 shares of the company traded hands, compared to its average volume of 3,227,132. Amicus Therapeutics has a fifty-two week low of $4.41 and a fifty-two week high of $16.60. The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39.

In related news, Director Michael Raab sold 10,000 shares of the stock in a transaction that occurred on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $142,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John F. Crowley sold 71,735 shares of the stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $14.75, for a total transaction of $1,058,091.25. Following the sale, the chief executive officer now directly owns 380,723 shares of the company’s stock, valued at $5,615,664.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 628,224 shares of company stock valued at $9,024,003. Company insiders own 3.40% of the company’s stock.

Several research firms have commented on FOLD. BidaskClub cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Chardan Capital upped their target price on shares of Amicus Therapeutics from $12.50 to $17.50 and gave the stock a “buy” rating in a research report on Thursday, August 10th. J P Morgan Chase & Co reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Robert W. Baird reaffirmed an “outperform” rating and issued a $18.00 price target (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, Cowen Inc reaffirmed a “buy” rating and issued a $16.00 price target on shares of Amicus Therapeutics in a research note on Monday, August 14th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $17.81.

COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) Posts Earnings Results, Misses Expectations By $0.10 EPS” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/amicus-therapeutics-inc-fold-releases-earnings-results-misses-expectations-by-0-10-eps/1760005.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Earnings History for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees
Free Agency Season Has Finally Heated Up
Free Agency Season Has Finally Heated Up


Leave a Reply

 
© 2006-2017 BBNS.